Growth and development in girls with Turner's syndrome during early therapy with low doses of estradiol

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S157-S163 ◽  
Author(s):  
K.W. KASTRUP ◽  
_ _
Keyword(s):  
Growth Velocity ◽  
Final Height ◽  
Bone Age ◽  
Growth Spurt ◽  
First Year ◽  
Turner's Syndrome ◽  
Turner’S Syndrome ◽  
Early Therapy ◽  
Group I ◽  
Group Ii

Abstract Early therapy with a low dose of estrogen (estradiol-17β) was given to 33 girls with Turner's syndrome (T.s.) for a period of 4 years. The dose (0.25-2 mg/day) was adjusted every 3 months to maintain plasma estradiol in the normal concentration range for bone age. Growth velocity was compared with that of untreated girls with T.s. All girls were above age 10 years. Bone age was below 10 years in 11 girls (group I) and above 10 years in 22 girls (group II). Growth velocity in the first year of treatment in group I 7.5 ± 1.3 cm (SD) with mean SD score (SDS) of +4.3 and in group II 4.9 ± 1.3 with mean SDS of +3.5. Growth velocity decreased in the following years to 1.6 ± 1.0 cm, SDS -1.44 in group I and 0.9 ± 0.6cm, SDS -2.34 in group II during the fourth year. Withdrawal bleeding occurred in 16 girls of group II after the mean of 23 (range 15-33) months and in 3 girls of group I after 15 to 51 months of treatment. The treatment did not cause an inappropriate acceleration of pubertal development. Breast development appeared in most girls by 3 months of treatment. Pubic hair appeared by 12 months of treatment in group I; it was present in most girls in group II at start of treatment. Final height is known for 12 girls of group II; it was 144.2 ± 4.5 cm. The final height as predicted at the start of therapy was 142.2 ± 5.3 cm. Bone age advanced in the first year of treatment by 2 years. Early treatment with small doses of estrogens induces a growth spurt and normalizes the events of puberty. This will presumably decrease the psychological risks associated with abnormally delayed development.

scholarly journals Lack of Effect of GnRH Agonists on Final Height in Girls with Advanced Puberty: A Randomized Long-Term Pilot Study

1999 ◽  
Vol 84 (10) ◽  
pp. 3575-3578 ◽  
Author(s):  
C. Bouvattier ◽  
J. Coste ◽  
D. Rodrigue ◽  
C. Teinturier ◽  
J. C. Carel ◽  
...  
Keyword(s):  
Final Height ◽  
Bone Age ◽  
Age And Growth ◽  
Controlled Study ◽  
Gnrh Agonists ◽  
Clear Cut ◽  
Group I ◽  
Group Ii ◽  
Predicted Height

Abstract GnRH agonists improve final height in girls with “true” precocious puberty. To test if a comparable effect can be obtained in older girls, we performed a long-term controlled study in 30 caucasian girls whose puberty started between 8.4 and 10 yr (9.4 ± 0.1 yr), a variant of normal called “advanced” puberty. At entry into trial, these girls had clinical, biological, and sonographic manifestations of puberty and a bone age greater than 10.9 yr. They were randomized 2:1 to receive 3.75 mg triptorelin im every 4 weeks for 2 yr (n = 20, group I) or no treatment (n = 10, group II). Mean height at inclusion was 135.2 ± 4.3 cm (+0.6 sds) in group I, 136.1 ± 4.2 cm (+0.8 sds ) in group II, with target height 157.6 ± 4.3 cm (group I) and 157.8 ± 4.7 cm (group II), and predicted height (Bayley-Pinneau) 154.1 ± 3.9 cm and 155.2 ± 3.7 cm. Although GnRH agonists transiently delayed sexual maturation as well as bone age and growth rate, they had no clear-cut long-standing effect, and final height was comparable in treated (157.6 ± 4.0 cm) and untreated girls (156.1 ± 5.3 cm) (NS).

A regression method including chronological and bone age for predicting final height in Turner's syndrome, with a comparison of existing methods

1996 ◽  
Vol 85 (4) ◽  
pp. 413-420 ◽  
Author(s):  
A van Teunenbroek ◽  
Th Stijnen ◽  
B Otten ◽  
S de Muinck Keizer-Schrama ◽  
RW Naeraa ◽  
...  
Keyword(s):  
Final Height ◽  
Bone Age ◽  
Regression Method ◽  
Turner's Syndrome ◽  
Turner’S Syndrome

scholarly journals Near Normalization of Final Height with Adapted Doses of Growth Hormone in Turner’s Syndrome

1998 ◽  
Vol 83 (5) ◽  
pp. 1462-1466 ◽  
Author(s):  
Jean-Claude Carel ◽  
Laurence Mathivon ◽  
Christine Gendrel ◽  
Jean-Pascal Ducret ◽  
Jean-Louis Chaussain
Keyword(s):  
Growth Hormone ◽  
Final Height ◽  
Turner's Syndrome ◽  
Turner’S Syndrome

Effect on growth of patients with Turner's syndrome treated with low estrogen doses

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S153-S156 ◽  
Author(s):  
MICHAEL B. RANKE ◽  
FRANK HAUG ◽  
WERNER F. BLUM ◽  
WERNER ROSENDAHL ◽  
ANDREA ATTANASIO ◽  
...  
Keyword(s):  
Bone Age ◽  
Height Velocity ◽  
Turner's Syndrome ◽  
Low Doses ◽  
Turner’S Syndrome ◽  
Control Data ◽  
End Of Treatment ◽  
Group A ◽  
One Year ◽  
Group B

ABSTRACT In 33 patients with Turner's syndrome growth during a one year period of treatment with low doses of estrogens was evaluated (group A: (N=12) PresomenR 5–9 μg/kg d; group B: (N=9) PresomenR 10–21 μg/kg d; group C: (N=12) ethinylestradiol 45–155 ng/kg d) and compared to a group (N=37) of untreated patients. The auxological evaluation was made using SDS derivations based on control data derived from 150 untreated patients. Based on chronological age (CA) SDS levels for height velocity and the increments in height at the end of treatment increased marginally. Compared to untreated patients no effect was seen when calculations were based on bone age (BA) due to an advancement in bone maturity. It is concluded that low doses of estrogens are not suitable to improve the height development in Turner's syndrome.

scholarly journals THE EFFECT OF STANOZOLOL ON FINAL HEIGHT AND SKELETAL MATURATION IN TURNER'S SYNDROME

1993 ◽  
Vol 33 ◽  
pp. S46-S46
Author(s):  
M Satoh ◽  
H Yano ◽  
T Tanaka ◽  
A Tanae ◽  
I Hibi
Keyword(s):  
Final Height ◽  
Skeletal Maturation ◽  
Turner's Syndrome ◽  
Turner’S Syndrome

The Relationship Between Salivary Dehydroepiandrosterone Sulphate (DHEAS) Levels and Skeletal Maturation Parameters Before and During Pubertal Growth Spurt in Children

2021 ◽  
Vol 15 (2) ◽  
Author(s):  
Tahseen Sultana ◽  
Penmetcha Sarada ◽  
Namineni Srinivas ◽  
C H Sampath Reddy ◽  
S Ojass KUMAR ◽  
...  
Keyword(s):  
Skeletal Maturity ◽  
Cervical Vertebrae ◽  
Cervical Vertebra ◽  
Skeletal Maturation ◽  
Growth Spurt ◽  
P Value ◽  
Group I ◽  
Lateral Cephalograms ◽  
Group Ii ◽  
Two Stages

Objectives: This study aimed to assess the skeletal maturation by using salivary DHEAS levels and its correlation with existing skeletal maturity parameters represented by cervical vertebrae and MP3 region radiographs in adolescents in pre-pubertal and pubertal age groups. Methods: In this study, 80 children in the age range of 8 - 14 years were divided into two equal groups based on their chronological age as group I (pre-pubertal group) and group II (pubertal group). Pre-existing lateral cephalograms and medial phalanx of third finger (MP3) radiographs of their left hands were assessed. The levels of the DHEAS of each individual were analysed by ELISA kit. ANOVA with post-hoc Tukey’s test and student t-test were used for statistical analysis. P-value < 0.05 was considered significant. Results: The mean level of DHEAS values shown in the present study was 4.36 +/- 0.32 ng/mL in group I and 5.73+/-0.39 ng/mL in group II. This study showed that in group I, more subjects were in stage 1 of cervical vertebral maturation than stage 2 and there were significant differences between the two stages (P-value = 0.011); also, in group II, more subjects were in stage 3 than 4 and there were significant differences between the two stages (P-value = 0.017). This study revealed the highest salivary DHEAS levels to be in the F stage of pre-pubertal MP3 development in addition to the H stage of MP3 development in pubertal children. This study noted that there were significant differences for salivary DHEAS levels between males and females not only in pre-pubertal (P-value = 0.031), but also in pubertal stages (P-value < 0.001). Conclusions: Salivary DHEAS, like cervical vertebra and MP3 radiographs, can be used for growth assessment in young adolescents.

Comparison of AdvanSync2® and Twin Block Appliances in Treatment of Class II Malocclusion With Retrognathic Mandible—An Observational Retrospective Study

2021 ◽  
pp. 030157422110572
Author(s):  
Ankit Kumar Shahi ◽  
Payal Sharma ◽  
Achint Juneja ◽  
Divya Shetty ◽  
Rishibha Bhardwaj ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Class Ii ◽  
T Test ◽  
Growth Spurt ◽  
Class Ii Malocclusion ◽  
Twin Block ◽  
Group I ◽  
Tissue Changes ◽  
Group Ii ◽  
Soft Tissue Changes

Objectives: To evaluate the treatment outcomes between Twin Block and AdvanSync2® appliances by comparing the skeletal, dentoalveolar, and soft tissue changes. Materials and Methods: Radiographic data of 20 patients were retrospectively analyzed. Data were selected from patients in their skeletal growth spurt as evaluated by the cervical vertebral maturation method (CVMI 2, 3, and 4), with class II malocclusion characterized with retrognathic mandible (ANB > 4°, SNB < 77°, FMA = 25 ± 5°, overjet > 5 mm). There were 10 patients in each group that underwent orthodontic correction for class II malocclusion: either using Twin Block or AdvanSync2®. Independent t test and Paired t test and chi-square tests were used for the data analysis. The level of statistical significance was set at P value ≤.05. Results: The chronological and skeletal age were similar in both the groups. Records were taken for the functional treatment with mean treatment span of 8 ± 1 month. Changes in SNB (group I = 1.59°, group II = 3.11°) ( P < .01), Co-Gn (group I = 2.89 mm, group II = 5.34 mm), and U1-L1° (group I = −1.51°, group II = 2.97°) showed statistically different outcome between the groups, when the pre-post data were studied. Rest of the variables—cranial base, maxillary skeletal, mandibular skeletal, intermaxillary, vertical skeletal, maxillary dentoalveolar, mandibular dentoalveolar, and soft tissue—showed similar outcome ( P > .05). Conclusion: Both appliances lead to desirable outcomes in the correction of class II malocclusion. AdvanSync2® resulted in inducing more of changes in SNB and effective mandibular length as compared to Twin Block. Overjet and molar relation improved significantly with both the appliances. Both the appliances resulted in similar skeletal, dentoalveolar, and soft tissue changes.

Growth velocity and biological variables during puberty in achondroplasia

2018 ◽  
Vol 31 (4) ◽  
pp. 421-428 ◽  
Author(s):  
Mariana del Pino ◽  
Virginia Fano ◽  
Paula Adamo
Keyword(s):  
Growth Velocity ◽  
Adult Height ◽  
Peak Velocity ◽  
Final Height ◽  
Pubertal Development ◽  
Individual Growth ◽  
Growth Spurt ◽  
Adult Size ◽  
Biological Variables ◽  
The Mean

AbstractBackground:Achondroplasia is the most common form of inherited disproportionate short stature. Cross-sectional design studies of height show that, during childhood, height standard deviation scores (SDS) declines steadily and reaches a mean adult height at −6.42 and −6.72 SDS. However, there is a lack of knowledge about longitudinal growth and biological variables during puberty for children with achondroplasia. Here we report the growth velocity and biological parameters during puberty in children with achondroplasia.Methods:The study was an observational, cohort study. A total of 23 patients, 15 girls and eight boys with achondroplasia, who reached adult size were included. Growth data was collected from mid-childhood until final height by the same trained observer. Individual growth curves were estimated by fitting the Preece-Baines model 1 (PB1) to each individual’s height for age data. Pubertal development was scored on Tanner scale on each visit.Results:In boys with achondroplasia the mean adult height was 129.18 cm. Age and velocity at peak velocity in puberty were 13.89 years and 4.86 cm/year, respectively. The adolescent gain was 20.40 cm. Mean age at genital development 2 and 5 were 12.16 (0.60) and 14.97 (0.88), respectively. In girls the mean adult height was 118.67 cm. Age and velocity at peak velocity in puberty were 11.45 years and 4.40 cm/year, respectively. The adolescent gain was 19.35 cm. Mean age at breast 2 and 4 were 10.20 (1.24) and 12.49 (1.07), respectively.Conclusions:Children with achondroplasia experienced an adolescent growth spurt, which was similar in shape and half the magnitude of the non-achondroplasia population.

Standards for Growth and Final Height in Turner's Syndrome

1990 ◽  
Vol 79 (2) ◽  
pp. 182-190 ◽  
Author(s):  
R. W. NAERAA ◽  
J. NIELSEN
Keyword(s):  
Final Height ◽  
Turner's Syndrome ◽  
Turner’S Syndrome
Sign in / Sign up

Export Citation Format

Share Document